The ability of ASC-CCM sEVs, particularly those enriched with TSG-6, to modulate microglial activation suggests their potential as therapeutic agents for neurodegenerative diseases and other conditions with chronic inflammation. This evidence concerns the gene TNFAIP6 and neurodegenerative disease.